- Home
- DSGN
as 07-26-2024 4:00pm EST
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 193.2M | IPO Year: | 2021 |
| Target Price: | $6.75 | AVG Volume (30 days): | 178.1K |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.94 - $8.31 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Design Therapeutics Inc. (DSGN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Berger Heather A. | DSGN | Director | Mar 25 '24 | Buy | $3.74 | 1,300 | $4,865.77 | 1,300 | SEC Form 4 |
| Schmid John P. | DSGN | Director | Mar 22 '24 | Buy | $3.62 | 9,156 | $33,132.82 | 9,156 | SEC Form 4 |
| Schmid John P. | DSGN | Director | Mar 22 '24 | Buy | $3.74 | 17,809 | $66,605.66 | 26,965 | SEC Form 4 |
Latest Design Therapeutics Inc. News
DSGN Breaking Stock News: Dive into DSGN Ticker-Specific Updates for Smart Investing
GuruFocus.com
3 months ago
Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic Review
GlobeNewswire
3 months ago
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
MT Newswires
3 months ago
--Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral
GlobeNewswire
3 months ago
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
Simply Wall St.
4 months ago
Independent Director of Design Therapeutics Picks Up 88% More Stock
Simply Wall St.
4 months ago
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Insider Monkey
4 months ago
Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript
Thomson Reuters StreetEvents
4 months ago
Q4 2023 Design Therapeutics Inc Earnings Call
Compare DSGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DSGN Design Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.